PBAC's latest decision on Tebentafusp: Recommended with restriction (2023). Considered for Treatment of HLA-A*02:01-positive adult patients with advanced (unresectable or metastatic) uveal melanoma.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2023
Submissions
1
2023 → 2023
Eligible population
Adults aged 18 years or older with HLA-A*02:01-positive advanced (unresectable or metastatic) uveal melanoma who have not received prior systemic therapy for metastatic disease, with ECOG performance status 0 or 1.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
OS
Key trials
IMCgp100-202
Comparator
pembrolizumab
Economic model
CUA
ICER note
ICER value is redacted; economic analysis section is incomplete in the provided text.